Pharming Group N.V annual debt-to-equity ratio
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Debt-to-Equity Ratio Growth & History (PHAR)
Pharming Group N.V's debt-to-equity ratio was 0.06 for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.06 | −0.07 | −52.75% |
| 2024 | 2024-12-31 | 0.14 | −0.02 | −10.62% |
| 2023 | 2023-12-31 | 0.15 | −0.01 | −6.98% |
| 2022 | 2022-12-31 | 0.16 | 0.05 | +50.42% |
| 2021 | 2021-12-31 | 0.11 | 0.05 | +94.75% |
| 2020 | 2020-12-31 | 0.06 | −0.00 | −7.81% |
| 2019 | 2019-12-31 | 0.06 | — | — |
Pharming Group N.V quarterly debt-to-equity ratio
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.42 | −0.12 | −21.81% |
| Q1 2026 | 2026-03-31 | 0.43 | — | — |
| Q4 2025 | 2025-12-31 | 0.06 | −0.07 | −52.75% |
| Q3 2025 | 2025-09-30 | 0.49 | — | — |
| Q2 2025 | 2025-06-30 | 0.54 | — | — |
| Q4 2024 | 2024-12-31 | 0.14 | −0.02 | −10.62% |
| Q4 2023 | 2023-12-31 | 0.15 | −0.01 | −6.98% |
| Q4 2022 | 2022-12-31 | 0.16 | 0.05 | +50.42% |
| Q4 2021 | 2021-12-31 | 0.11 | — | — |
Pharming Group N.V debt-to-equity ratio trends
Over the last five fiscal years, Pharming Group N.V's debt-to-equity ratio increased from 0.06 to 0.06, a change of 0.01. The latest reported quarter, Q2 2026, shows 0.42.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...